Hyderabad startup PopVax makes personalised cancer vaccine for 34
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓Hyderabad startup PopVax is developing a personalised cancer vaccine for a 34-year-old pancreatic cancer patient using mRNA technology.
- ✓Founder Soham Sankaran said, “We’re making a personalized cancer vaccine for Yash, a 34 year-old pancreatic cancer patient, in the open with his consent.” The company uses genetic information to train immune systems.
Story at a Glance
- Category
- Indian Markets
- Reported By
- CNBC TV18
- Reading Speed
- 3 Minute(s)
- Market Focus
- India Economy
Hyderabad-based biotechnology company PopVax is developing a personalised cancer vaccine for a 34-year-old pancreatic cancer patient, using messenger RNA (mRNA) technology.
The vaccine is being designed using genetic information from the patient's tumour and is expected to be manufactured at the company's RNA Foundry facility in Hyderabad.
Soham Sankaran, founder of PopVax, announced the project in a post on X, saying the company was working on the vaccine with the patient's consent. PopVax has also invited external experts to review its design and contribute to the development process before manufacturing begins.
“We’re making a personalized cancer vaccine for Yash, a 34 year-old pancreatic cancer patient, in the open with his consent.”
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
CNBC TV18
Read the full, original unfiltered story directly on the publisher's portal.
This brief is for information only and is not investment advice. ArthNow is not a SEBI-registered investment adviser and does not publish buy or sell recommendations. Original reporting is credited to the publisher named above. Read our editorial policy or report an error.